【摘要】 【目的】观察奥扎格雷对急性冠脉综合征(ACS)患者血浆血管性血友病因子(vWF)含量的影响。【方法】选择80例ACS病人,其中急性心肌梗死(AMI)40例,不稳定心绞痛(UAP)40例,随机分为治疗组(常规治疗加奥扎格雷,n=40)和对照组(常规治疗,n=40),分别测定治疗前后病人血浆vWF含量。【结果】两组病人治疗前的血浆vWF明显增高,治疗后均有下降,奥扎格雷治疗组血浆vWF含量降低幅度(37%)大于对照组(21%)。【结论】用奥扎格雷治疗ACS病人,能显著降低血浆vWF含量。更多还原

【Abstract】 【Objective】To observe the influence of azagral sodium to the plasma von Willebrand factor(vWF) in patients with acute coronary syndrome(ACS).【Methods】Eighty patients with ACS,40 of them with acute myocardiol infarction(AMI) and 40 with unstable angina pectoris(UAP) were examined.They were divided into two groups: treatment and control group,40 cases in each group.All patients were measured the plasma levels of vWF before and after treatment with medicine.【Results】The plasma level of vWF in the treatment group were siginificantly lower than that of the control group(P<0.05).【Conclusion】After the treatment of azagral sodium in patients with ACS,the plasma level of vWF is remarkably reduced.更多还原